Collegium Pharmaceutical
COLL
Cars.com
CARS
Halozyme Therapeutics
HALO
4
Lantheus
LNTH
5
Precision Drilling
PDS
US Stock MarketDetailed Quotes
WST West Pharmaceutical Services
- 216.050
- -0.070-0.03%
Trading Apr 29 12:31 ET
15.52BMarket Cap33.92P/E (TTM)
217.250High213.548Low156.98KVolume215.885Open216.120Pre Close33.90MTurnover0.22%Turnover Ratio32.29P/E (Static)71.85MShares371.79652wk High5.79P/B15.41BFloat Cap187.43052wk Low0.82Dividend TTM71.32MShs Float471.465Historical High0.38%Div YieldTTM1.71%Amplitude3.185Historical Low215.921Avg Price1Lot Size
West Pharmaceutical Services Key Stats
Quarterly+Annual
YOY
| (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | 9.48%129.4M | -15.85%653.4M | -20.49%190.1M | -21.73%180.1M | -2.48%165M | -14.41%118.2M | 7.25%776.5M | 3.60%239.1M | 36.23%230.1M | -2.25%169.2M |
| Net income from continuing operations | -22.12%89.8M | -16.97%492.7M | -5.04%130.1M | -15.69%136M | -28.24%111.3M | -17.64%115.3M | 1.28%593.4M | 33.01%137M | 33.75%161.3M | -17.72%155.1M |
| Operating gains losses | ---- | -196.15%-15.4M | ---- | ---- | ---- | ---- | -125.87%-5.2M | 45.28%-16.8M | --0 | --2.2M |
| Depreciation and amortization | 12.36%40M | 13.18%155.4M | 13.37%40.7M | 12.61%40.2M | 14.08%38.9M | 12.66%35.6M | 13.85%137.3M | 15.43%35.9M | 19.80%35.7M | 13.29%34.1M |
| Deferred tax | ---- | -109.33%-3.5M | ---- | ---- | ---- | ---- | 221.75%37.5M | ---- | ---- | ---- |
| Other non cash items | 43.24%-2.1M | -570.00%-4.7M | -65.52%5M | -90.91%-2.1M | 33.90%-3.9M | 43.08%-3.7M | -92.48%1M | -53.53%14.5M | 82.54%-1.1M | -43.90%-5.9M |
| Change In working capital | 100.29%100K | 114.22%2.9M | -12.64%23.5M | -100.40%-100K | 155.73%14.1M | 26.07%-34.6M | -36.00%-20.4M | -76.75%26.9M | 177.02%24.8M | 47.62%-25.3M |
| -Change in receivables | ---- | -1,570.00%-58.8M | ---- | ---- | ---- | ---- | 111.24%4M | ---- | ---- | ---- |
| -Change in inventory | ---- | 411.11%42M | ---- | ---- | ---- | ---- | 72.89%-13.5M | ---- | ---- | ---- |
| -Change in payables and accrued expense | ---- | -34.09%2.9M | ---- | ---- | ---- | ---- | 257.14%4.4M | ---- | ---- | ---- |
| -Change in other current assets | ---- | 72.77%-5.8M | ---- | ---- | ---- | ---- | -215.14%-21.3M | ---- | ---- | ---- |
| -Change in other working capital | ---- | 276.67%22.6M | ---- | ---- | ---- | ---- | -89.03%6M | ---- | ---- | ---- |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | 9.48%129.4M | -15.85%653.4M | -20.49%190.1M | -21.73%180.1M | -2.48%165M | -14.41%118.2M | 7.25%776.5M | 3.60%239.1M | 36.23%230.1M | -2.25%169.2M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 21.30%-71.3M | -2.71%-378.7M | 3.68%-104.8M | 14.21%-82.1M | -23.26%-101.2M | -10.35%-90.6M | -27.93%-368.7M | -14.77%-108.8M | -61.93%-95.7M | -24.39%-82.1M |
| Capital expenditure reported | 21.30%-71.3M | -4.14%-377M | 3.50%-104.9M | 15.14%-81.3M | -32.89%-100.2M | -10.35%-90.6M | -27.20%-362M | -14.54%-108.7M | -65.74%-95.8M | -14.07%-75.4M |
| Net other investing changes | ---- | 74.63%-1.7M | 200.00%100K | -900.00%-800K | ---- | ---- | -86.11%-6.7M | -200.00%-100K | 107.69%100K | ---- |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | 21.30%-71.3M | -2.71%-378.7M | 3.68%-104.8M | 14.21%-82.1M | -23.26%-101.2M | -10.35%-90.6M | -27.93%-368.7M | -14.77%-108.8M | -61.93%-95.7M | -24.39%-82.1M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 45.76%-147M | -35.47%-622.6M | 63.64%-68.9M | -188.79%-64.4M | -23.47%-218.3M | -281.69%-271M | -56.54%-459.6M | -1,894.74%-189.5M | 70.35%-22.3M | -388.40%-176.8M |
| Net issuance payments of debt | 71.43%-200K | -1,050.00%-27.6M | 85.71%-100K | -483.33%-3.5M | -4,560.00%-23.3M | -16.67%-700K | 94.58%-2.4M | -16.67%-700K | 98.59%-600K | 0.00%-500K |
| Net common stock issuance | 50.07%-136M | -25.58%-566.6M | 69.17%-54.6M | -86.48%-52.4M | -7.34%-187.2M | -280.45%-272.4M | -103.06%-451.2M | -177,200.00%-177.1M | -2.18%-28.1M | -503.46%-174.4M |
| Cash dividends paid | -3.40%-15.2M | -3.68%-59.1M | -3.38%-15.3M | -3.57%-14.5M | -3.55%-14.6M | -4.26%-14.7M | -5.36%-57M | -4.96%-14.8M | -3.70%-14M | -7.63%-14.1M |
| Proceeds from stock option exercised by employees | -73.81%4.4M | -35.88%32.7M | 0.00%3.1M | -70.59%6M | -44.26%6.8M | 9.80%16.8M | 80.85%51M | -38.00%3.1M | 142.86%20.4M | 87.69%12.2M |
| Net other financing activities | ---- | ---2M | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 45.76%-147M | -35.47%-622.6M | 63.64%-68.9M | -188.79%-64.4M | -23.47%-218.3M | -281.69%-271M | -56.54%-459.6M | -1,894.74%-189.5M | 70.35%-22.3M | -388.40%-176.8M |
| Net cash flow | ||||||||||
| Beginning cash position | -43.25%484.6M | -4.52%853.9M | -45.37%490.9M | -43.97%446.2M | -32.10%601.8M | -4.52%853.9M | 17.27%894.3M | 23.26%898.6M | 10.83%796.3M | 32.74%886.3M |
| Current changes in cash | 63.48%-88.9M | -571.62%-347.9M | 127.70%16.4M | -70.03%33.6M | -72.24%-154.5M | -1,522.67%-243.4M | -136.43%-51.8M | -146.80%-59.2M | 223.99%112.1M | -226.52%-89.7M |
| Effect of exchange rate changes | 197.70%8.5M | -287.72%-21.4M | -256.55%-22.7M | 213.27%11.1M | -266.67%-1.1M | -224.29%-8.7M | 208.57%11.4M | -62.63%14.5M | 59.34%-9.8M | 98.51%-300K |
| End cash Position | -32.83%404.2M | -43.25%484.6M | -43.25%484.6M | -45.37%490.9M | -43.97%446.2M | -32.10%601.8M | -4.52%853.9M | -4.52%853.9M | 23.26%898.6M | 10.83%796.3M |
| Free cash flow | 110.51%58.1M | -33.32%276.4M | -34.66%85.2M | -26.43%98.8M | -30.92%64.8M | -50.71%27.6M | -5.67%414.5M | -4.05%130.4M | 20.88%134.3M | -12.34%93.8M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | Unqualified Opinion | -- | -- | -- | -- | -- | -- | -- | -- |
Market Insights
Discussing
Trade war escalates: What’s next for Chinese stocks?
🎙️Discussion 1. China-EU EV negotiations kick off recently. How do you think the negotiations will impact the performance of related stocks
Moo Earnings
Feb 17 19:21
Alibaba Q4 FY2024 Earnings Preview: Predict & Win Big! 🚀